INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022
25 mars 2022 09h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, March 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness...
INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 - International Conference on Alzheimer's and Parkinson's Diseases
15 mars 2022 08h00 HE
|
INmune Bio, Inc.
Conference Provides First Exposure of EU and UK AD Experts to INmune Bio’s Approach of Targeting Neuroinflammation and Glial Activation with XPro™ for Treatment of Alzheimer’s Disease ...
INmune Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference
14 mars 2022 16h30 HE
|
INmune Bio, Inc.
Boca Raton, FL, March 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient’s immune system...
INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business Update
03 mars 2022 16h00 HE
|
INmune Bio, Inc.
Cash of $74.8 million on December 31, 2021 Company to host conference call today, March 3, at 4:30pm ET Boca Raton, Florida, March 03, 2022 (GLOBE NEWSWIRE) -- INmune Bio,...
INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3
23 févr. 2022 09h00 HE
|
INmune Bio, Inc.
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Feb. 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a...
INmune Bio, Inc. to Present at the BIO CEO & Investor Conference
08 févr. 2022 09h00 HE
|
INmune Bio, Inc.
BOCA RATON, Florida., Feb. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer
25 janv. 2022 09h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Jan. 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness...
INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting
04 janv. 2022 09h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Jan. 04, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 San Antonio Breast Cancer Symposium
09 déc. 2021 09h01 HE
|
INmune Bio, Inc.
Data suggests in triple negative breast cancer that MUC4 predicts survival and resistance to immunotherapy and that INB03 reverses resistance by decreasing immunosuppression in the TME Boca...
INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS trial.
01 déc. 2021 09h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Dec. 01, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...